Towards selective pharmacological modulation of protein kinase C - opportunities for the development of novel antineoplastic agents
1992
Modulating Protein Kinase C for Cancer Treatment
Editorial
Evidence: moderate
Author Information
Author(s): A. Gescher
Primary Institution: Cancer Research Campaign Experimental Chemotherapy Group, B47ET, UK
Hypothesis
Can selective pharmacological modulation of protein kinase C (PKC) lead to the development of new anticancer drugs?
Conclusion
The study highlights the potential of PKC modulators like bryostatin 1 in cancer treatment, despite uncertainties regarding their selectivity and effects.
Supporting Evidence
- Bryostatin 1 activates PKC and shows antitumor activity in various cancer models.
- PKC activation can lead to both cell growth and cell death, depending on the cell type.
- Phorbol esters, which activate PKC, have been shown to promote tumor growth in some contexts.
Takeaway
Scientists are exploring ways to change how a protein called PKC works in cells to help fight cancer. Some substances can help, but it's tricky because they can also cause problems.
Limitations
The effects of PKC modulation can vary greatly between different cell types, making it difficult to predict outcomes.
Want to read the original?
Access the complete publication on the publisher's website